Tenofovir Disoproxil

Tenofovir Disoproxil (Bis (POC) -PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

Product Specifications

CAS Number

[201341-05-1]

Product Name Alternative

Bis (POC) -PMPA; GS 4331

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HBV; HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Tenofovir-Disoproxil.html

Purity

99.52

Solubility

DMSO : ≥ 38 mg/mL

Smiles

O=C(OC(C)C)OCOP(OCOC(OC(C)C)=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)=O

Molecular Formula

C19H30N5O10P

Molecular Weight

519.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Murphy RA, et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity. Int J Mol Sci. 2017 Mar 1;18 (3) |[2]Musumeci G, et al. M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep. 2017 Feb 1;7:41018|[3]Wahl A, et al. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep. 2017 Feb 1;7:41098|[4]Menne S, Cote PJ, Korba BE, Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul;49 (7) :2720-8.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

HIV-1

Citation 01

Department od Analytical Chemistry, Charles University. 2019 Jun.|Pharmaceuticals (Basel) . 2025 Oct 16;18 (10) :1560.|Adv Sci (Weinh) . 2024 Aug 19:e2403058.|Cell. 2025 Sep 4;188 (18) :4896-4912.e19.|Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.|J Gastroenterol. 2021 Feb;56 (2) :168-180.|J Neuroimmune Pharmacol. 2017 Dec;12 (4) :682-692.|J Neuroimmune Pharmacol. 2021 Mar;16 (1) :159-168.|Sci Rep. 2019 Nov 20;9 (1) :17158.